Comparative Pharmacology
Head-to-head clinical analysis: PROCAN versus PROCAN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAN versus PROCAN SR.
PROCAN vs PROCAN SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procainamide is a class Ia antiarrhythmic agent that blocks sodium channels, slowing conduction velocity and prolonging the refractory period. It also has weak anticholinergic effects.
Procainamide is a class Ia antiarrhythmic agent that blocks sodium channels, reducing myocardial excitability and conduction velocity, and prolonging the refractory period.
250 mg orally every 6 hours; extended-release product: 500 mg orally every 6 hours.
Oral: 50 mg/kg/day divided every 6 hours; typical adult dose: 250-500 mg every 6 hours. For sustained-release (Procan SR): 500-1000 mg every 6 hours.
None Documented
None Documented
Procainamide: 2.5-4.7 hours (increased to 4-6 hours in elderly or heart failure; prolonged in renal impairment). NAPA: 6-9 hours (active metabolite). Clinical context: Therapeutic monitoring requires measurement of both parent drug and metabolite due to NAPA's antiarrhythmic activity.
Procainamide: 2.5-4.7 hours (normal renal function); NAPA: 6-8 hours. In renal impairment, half-life prolonged up to 10-20 hours for procainamide and 40+ hours for NAPA.
Renal: 50-67% as unchanged drug and major metabolite N-acetylprocainamide (NAPA). Biliary/fecal: <10%.
Renal: 50-60% as unchanged procainamide; hepatic metabolism to N-acetylprocainamide (NAPA) which is also renally excreted; total renal excretion of procainamide + NAPA accounts for ~85% of dose; remainder fecal (<5%).
Category C
Category C
Class Ia Antiarrhythmic
Class Ia Antiarrhythmic